monoclonal antibody, interleukin-2, and sargramostim following stem cell transplantation in
treating patients who have neuroblastoma. Drugs used in chemotherapy work in different ways
to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can
locate tumor cells and either kill them or deliver tumor-killing substances to them without
harming normal cells. Interleukin-2 and sargramostim may stimulate a person''s white blood
cells to kill cancer cells. It is not yet known if chemotherapy is more effective with or
without monoclonal antibody therapy, interleukin-2, and sargramostim following stem cell
transplantation in treating neuroblastoma.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: firstname.lastname@example.org
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.